BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36543932)

  • 1. Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease.
    Torices L; Mingo J; Rodríguez-Escudero I; Fernández-Acero T; Luna S; Nunes-Xavier CE; López JI; Mercadillo F; Currás M; Urioste M; Molina M; Cid VJ; Pulido R
    Eur J Hum Genet; 2023 May; 31(5):568-577. PubMed ID: 36543932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.
    Rodríguez-Escudero I; Oliver MD; Andrés-Pons A; Molina M; Cid VJ; Pulido R
    Hum Mol Genet; 2011 Nov; 20(21):4132-42. PubMed ID: 21828076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pathogenic role for germline PTEN variants which accumulate into the nucleus.
    Mingo J; Rodríguez-Escudero I; Luna S; Fernández-Acero T; Amo L; Jonasson AR; Zori RT; López JI; Molina M; Cid VJ; Pulido R
    Eur J Hum Genet; 2018 Aug; 26(8):1180-1187. PubMed ID: 29706633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
    Chen HH; Händel N; Ngeow J; Muller J; Hühn M; Yang HT; Heindl M; Berbers RM; Hegazy AN; Kionke J; Yehia L; Sack U; Bläser F; Rensing-Ehl A; Reifenberger J; Keith J; Travis S; Merkenschlager A; Kiess W; Wittekind C; Walker L; Ehl S; Aretz S; Dustin ML; Eng C; Powrie F; Uhlig HH
    J Allergy Clin Immunol; 2017 Feb; 139(2):607-620.e15. PubMed ID: 27477328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
    Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
    J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebellar phenotypes in germline PTEN mutation carriers.
    Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".
    Galatola M; Paparo L; Duraturo F; Turano M; Rossi GB; Izzo P; De Rosa M
    BMC Med Genet; 2012 Apr; 13():28. PubMed ID: 22520842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays, and macrocephaly.
    Wong CW; Or PMY; Wang Y; Li L; Li J; Yan M; Cao Y; Luk HM; Tong TMF; Leslie NR; Lo IF; Choy KW; Chan AML
    Autism Res; 2018 Aug; 11(8):1098-1109. PubMed ID: 29608813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
    Wang Q; Weisberg E; Zhao JJ
    Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort.
    Hendricks LAJ; Hoogerbrugge N; Venselaar H; Aretz S; Spier I; Legius E; Brems H; de Putter R; Claes KBM; Evans DG; Woodward ER; Genuardi M; Brugnoletti F; van Ierland Y; Dijke K; Tham E; Tesi B; Schuurs-Hoeijmakers JHM; Branchaud M; Salvador H; Jahn A; Schnaiter S; Anastasiadou VC; Brunet J; Oliveira C; Roht L; Blatnik A; Irmejs A; ; Mensenkamp AR; Vos JR
    Eur J Med Genet; 2022 Dec; 65(12):104632. PubMed ID: 36270489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN hamartoma tumor syndromes.
    Blumenthal GM; Dennis PA
    Eur J Hum Genet; 2008 Nov; 16(11):1289-300. PubMed ID: 18781191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
    Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
    Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dermatological and skeletal features associated with PTEN variant in PTEN hamartoma tumor syndrome.
    Comeau D; Allain V; Maillet-Lebel N; Ben Amor M
    Eur J Med Genet; 2023 Aug; 66(8):104798. PubMed ID: 37307869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
    Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
    N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Human PTEN-L in a Yeast Heterologous Model Unveils Specific N-Terminal Motifs Controlling PTEN-L Subcellular Localization and Function.
    Fernández-Acero T; Bertalmio E; Luna S; Mingo J; Bravo-Plaza I; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
    Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
    PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN-opathies: from biological insights to evidence-based precision medicine.
    Yehia L; Ngeow J; Eng C
    J Clin Invest; 2019 Feb; 129(2):452-464. PubMed ID: 30614812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN in Hereditary and Sporadic Cancer.
    Ngeow J; Eng C
    Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31570378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.
    Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C
    Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
    Orloff MS; Eng C
    Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.